North America Vitamin B12 Market Size & Outlook, 2025-2033
North America Vitamin B12 Market Insights
- As highlighted in Deep Market Insights analysis, the North America Vitamin B12 Market, valued at USD 64.78 Million in 2024, is estimated to achieve USD 114.18 Million by 2033.
- The market is estimated to grow at a CAGR of 6.55% spanning 2026 to 2033.
- By market size, Cyanocobalamin led the Form category in 2024.
- The Form segment led by Hydroxocobalamin is estimated to post the fastest growth, sustaining its position as the most lucrative during the forecast timeframe.
Source: DMI Analysis Company Publications, Primary Interviews.
Other Key Findings
- North America held 30.98% share of the global Vitamin B12 Market size in 2024.
- United States is expected to remain the largest contributor to the global market size by 2033.
- By 2033, United States is anticipated to record the highest growth in North America, with the market size expected to reach USD 85.51 Million.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 64.78 Million |
| Market Size In 2033 | USD 114.18 Million |
| Largest segment | Cyanocobalamin |
| Units | Revenue in USD Million |
| CAGR | 6.55% (2025-2033) |
| Segmnetation Covered | |
| North America |
|
| Form |
|
| Application |
|
| Route |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
North America Vitamin B12 Market Country 2025-2033 (USD Million)
| North America | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | XX.x | XX.x | XX.x | 47.46 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Canada | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
North America Vitamin B12 Market Form 2025-2033 (USD Million)
| Form | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cyanocobalamin | XX.x | XX.x | XX.x | 30.22 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Methylcobalamin | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Hydroxocobalamin | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
North America Vitamin B12 Market Application 2025-2033 (USD Million)
| Application | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharma | XX.x | XX.x | XX.x | 32.62 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Supplements | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Fortified food | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.
North America Vitamin B12 Market Route 2025-2033 (USD Million)
| Route | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oral | XX.x | XX.x | XX.x | 32.51 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Injectable | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Sublingual | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: DMI Analysis Company Publications, Primary Interviews.